Am­gen lines up ex­pan­sion to Ote­zla's $13B fran­chise; Chi­na OKs 'break­through' use of PD-1

Am­gen’s $13 bil­lion drug Ote­zla is be­ing lined up for an add-on OK as ri­vals at Bris­tol My­ers cir­cle in with a ri­val ther­a­py.

The Big Phar­ma play­er an­nounced Mon­day that it’s sub­mit­ted an sN­DA for mild-to-mod­er­ate plaque pso­ri­a­sis, look­ing to build on the mod­er­ate-to-se­vere ap­proval al­ready in hand. Am­gen bought out the drug from Cel­gene as the biotech was fin­ish­ing lin­ing up its big merg­er with Bris­tol My­ers. Bris­tol, though, has been fo­cused on its ri­val pso­ri­a­sis con­tender deu­cravac­i­tinib, where re­searchers have been rack­ing up pos­i­tive head-to-head da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER